Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSD, Psilocybin, and DMT Comparison in Healthy Participants
NCT06899334Phase 1Recruiting
- Sponsor
- University Hospital Basel
- Start
- Apr 2025
- Primary completion
- Aug 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lysergide, psilocybin and DMT in psychiatric disorders (4 arms), sponsored by University Hospital Basel. Primary endpoint: Altered state of consciousness profile (5D-ASC) at 18 months. Started Apr 2025; status: recruiting.
02
Drugs
LysergidepsilocybinDMT
03
Conditions
psychiatric disorders
Beyond the preview
Go deeper on NCT06899334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06899334.